<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921647</url>
  </required_header>
  <id_info>
    <org_study_id>YH4808-108</org_study_id>
    <nct_id>NCT01921647</nct_id>
  </id_info>
  <brief_title>The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects</brief_title>
  <acronym>YH4808-108</acronym>
  <official_title>The Exploration for Pharmacodynamics and Pharmacokinetic Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is not only to explore pharmacokinetic interaction after single
      oral administration but also pharmacodynamics interaction after multiple oral administration
      of YH4808, amoxicillin and clarithromycin each separately versus coadministration of YH4808,
      amoxicillin and clarithromycin in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax, AUClast of YH4808, M3, amoxicillin, clarithromycin, 14-hydroxyclarithromycin</measure>
    <time_frame>pre dose, 16 times after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, AUClast of M8, AUCinf, t1/2, Tmax of YH4808, M3, M8, amoxicillin, clarithromycin, 14-hydroxyclarithromycin</measure>
    <time_frame>pre dose, 16 times after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>YH4808, amoxicillin, clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808, amoxicillin and clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 and amoxicillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nexium, amoxicillin and clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808</intervention_name>
    <arm_group_label>YH4808, amoxicillin, clarithromycin</arm_group_label>
    <arm_group_label>YH4808, amoxicillin and clarithromycin</arm_group_label>
    <arm_group_label>YH4808 and amoxicillin</arm_group_label>
    <other_name>experimental drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium</intervention_name>
    <arm_group_label>nexium, amoxicillin and clarithromycin</arm_group_label>
    <other_name>active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <arm_group_label>YH4808, amoxicillin, clarithromycin</arm_group_label>
    <arm_group_label>YH4808, amoxicillin and clarithromycin</arm_group_label>
    <arm_group_label>YH4808 and amoxicillin</arm_group_label>
    <arm_group_label>nexium, amoxicillin and clarithromycin</arm_group_label>
    <other_name>experimental drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
    <arm_group_label>YH4808, amoxicillin, clarithromycin</arm_group_label>
    <arm_group_label>YH4808, amoxicillin and clarithromycin</arm_group_label>
    <arm_group_label>nexium, amoxicillin and clarithromycin</arm_group_label>
    <other_name>experimental drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. healthy male age 20 to 55 over 55kg with Ideal body weight(BMI:18.5~25)

          2. Subject who has no congenital, chronic disease and disease symptoms in medical
             examination result

          3. Subject who is judged to be eligible by principal investigator or sub-investigator
             according to various reasons including their abnormal test results(clinical laboratory
             test, 12-lead GCG etc)

        Exclusion Criteria:

          1. Subject who is hypersensitive to components contained in YH4808 or this drug

          2. Subject who has history or presence of clinically significant diseases in liver,
             kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system,
             blood tumor, cardiovascular, urinary system, and mental disorder

          3. Subject who has history of surgical operation or diseases related to gastrointestinal
             symptom (e.g. Crohn's disease, ulcer etc except appendectomy or simple for hernia)

          4. Other exclusions apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min soo Park, Ph.D, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2013</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety/tolerability and pharmacokinetics/pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

